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Because retinal ischemia is a common cause of vision
loss, we sought to determine the effects of ischemia on
neuroretinal function and survival in murine oxygen-
induced retinopathy (OIR) and to define the role of
endogenous erythropoietin (EPO) in this model. OIR is
a reproducible model of ischemia-induced retinal neo-
vascularization; it is used commonly to develop antian-
giogenic strategies. We investigated the effects of
ischemia in murine OIR on retinal function and
neurodegeneration by electroretinography and detailed
morphology. OIR was associated with significant neu-
roretinal dysfunction, with reduced photopic and sco-
topic ERG responses and reduced b-wave/a-wave ratios
consistent with specific inner-retinal dysfunction. OIR
resulted in significantly increased apoptosis and atro-
phy of the inner retina in areas of ischemia. EPO defi-
ciency in heterozygous Epo-Tag transgenic mice was
associatedwithmore profound retinal dysfunction after
OIR, indicated by a significantly greater suppression of
ERG amplitudes, but had no measurable effect on the
extent of retinal ischemia, preretinal neovasculariza-
tion, or neuroretinal degeneration in OIR. Systemic ad-
ministration of recombinant EPO protected EPO-defi-
cient mice against this additional suppression, but EPO
supplementation in wild-type animals with OIR did not
rescue neuroretinal dysfunction or degeneration. Mu-
rine OIR offers a valuable model of ischemic neuroreti-
nal dysfunction and degeneration in which to investigate
adaptive tissue responses and evaluate novel therapeutic
approaches. Endogenous EPO can protect neuroretinal
1726function in ischemic retinopathy. (Am J Pathol 2012, 180:
1726–1739; DOI: 10.1016/j.ajpath.2011.12.033)
Retinal ischemia is a common feature of major causes of
vision loss including diabetes,1 retinal vascular occlu-
sion,2,3 and retinopathy of prematurity.4 The retina has a
uniquely high metabolic demand for oxygen that is nor-
mally met by a highly efficient vascular supply. Insuffi-
ciency of the retinal circulation causes neuroretinal dys-
function and degeneration. Focal retinal ischemia results
in selective damage to specific subpopulations of retinal
neurons and can result in cellular death by apoptosis or
necrosis.5 Dysfunction and degeneration of the inner ret-
ina in ischemic retinopathies leads directly to vision loss
and is associated with characteristic changes in electro-
retinogram (ERG) responses.6–8
Endogenous adaptive responses can help protect
against ischemic injury. In the eye, however, the associ-
ated angiogenic response is typically aberrant, causing
severe vision loss through edema, hemorrhage, and fi-
brosis. Aberrant ischemia-induced angiogenesis exacer-
bates hypoxic neuroretinal injury and is the target of novel
therapies, including inhibitors of vascular endothelial
growth factor (VEGF). However, treatments with nonspe-
cific angiostatic agents fail to take into account appropri-
ate beneficial endogenous adaptive responses to hyp-
oxia and so risk compromising critical neuroprotective
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and more effective by considering how to protect and
preserve these responses.
Ischemia-induced retinal dysfunction and degenera-
tion are features of rodent models of retinal vascular
occlusion9,10 and diabetes.11,12 However, the angio-
genic response in these models is unpredictable. Oxy-
gen-induced retinopathy (OIR) in the mouse is a reliable
model of ischemia-induced retinal neovascularization13
that has been used extensively in the investigation and
preclinical development of novel antiangiogenic treat-
ments such as inhibitors of VEGF14–16 and erythropoietin
(EPO).17–19 However, the nature and extent of ischemic
neurodegeneration and dysfunction has not been previ-
ously evaluated in murine OIR. Studies in the rat have
demonstrated ischemia-induced retinal dysfunction after
OIR that results in abnormal ERG a-wave, ERG b-wave,
and oscillatory potentials (OPs).8,20–22 The availability of
transgenic strains, however, makes the mouse an attrac-
tive species to investigate disease mechanisms and to
develop therapeutic strategies addressing ischemia-in-
duced retinal neurodegeneration and neovascularization.
EPO is a widely distributed oxygen-regulated hormone
and paracrine cytokine that acts on multiple pathways,
including erythropoiesis, angiogenesis, and neuroprotec-
tion. Expression of EPO is predominantly in the kidney
and liver postnatally,23 but local expression is also evi-
dent in neuronal tissues, including the brain24,25 and
retina.26,27 Specific disease processes may influence the
location of EPO receptors in the retina.28 Because EPO is
proangiogenic and is expressed in the retina, it presents
a potential target for antiangiogenic therapy in retinal
neovascular disorders. Vitreous EPO levels are elevated
in patients with ischemic retinal diseases, including reti-
nal vascular occlusion,29 diabetic retinopathy,17,30,31 and
retinopathy of prematurity.32 In the hypoxic phase of mu-
rine OIR, retinal EPO expression is increased, and sup-
plementation with high doses of EPO can be proangio-
genic in this context.33 Systemic EPO supplementation
also has been shown to be an independent risk factor for
the development of retinopathy of prematurity in prema-
ture babies.34 Recent studies have advocated the use of
EPO inhibitors such as EPO-targeting short interfering
RNA (siRNA)18 or antibodies17 in the hypoxic phase of
OIR, to inhibit neovascularization.
There is emerging evidence that proangiogenic factors
such as VEGF and EPO have important roles in neuro-
protection in the retina35,36 and in the central nervous
system.37 Supplemental EPO can protect the adult retina
from ischemic damage38 and from light-induced retinal
degeneration.26,39 Many retinal neuronal cell types ex-
press receptors for EPO (EPO-R),40,41 and EPO-R ex-
pression is up-regulated after retinal ischemia.38 EPO
may also have an important role in neurodevelopment in
the eye and the brain.24 Neurodevelopmental abnormal-
ities in premature infants with systemic EPO deficiency42
can be ameliorated by EPO supplementation.43 To date,
however, similar studies examining the effects of EPO on
retinal neurodevelopment have not been performed.
The purpose of the present study was to determine the
effect of ischemia on neuroretinal function and survival inmurine OIR and to investigate the role of EPO in this
model. We investigated the effect of ischemia in murine
OIR on inner retinal function and neurodegeneration by
electroretinography and detailed morphology, both in the
short and long term. Using this model, we found that
endogenous EPO can protect neuroretinal function.
Materials and Methods
Animals
The Epo-Tag transgenic mouse is described else-
where.44 Briefly, Epo-Tag mice have a 2.7-kb insertion of
the viral simian virus 40 T (SV40T) antigen coding se-
quence into the 5= untranslated region of the Epo gene.44
This insertion leads to relative EPO deficiency, although
homozygous mice do have a low level of EPO production
from transcripts running through the viral polyA signal
into the EPO coding sequence. Homozygous Epo-
Tag/ mice are profoundly anemic, whereas heterozy-
gous Epo-Tag/ adult mice are only mildly anemic.45
We chose to evaluate heterozygous Epo-Tag mice in the
present study, because the severe anemia in Epo-Tag/
mice might influence OIR through an effect on oxygen
delivery to the eye. Epo-Tag/mice were maintained on
a C57Bl6J background (Harlan United Kingdom, Bices-
ter, UK) as mixed litters of Epo-Tag/ and wild-type
animals (Epo-Tag/). All animals were used with institu-
tional ethical approval and under a United Kingdom
Home Office project license and personal license. All
procedures were performed in accordance with the As-
sociation for Research in Vision and Ophthalmology
Statement for the Use of Animals in Ophthalmic and Vi-
sion Research.
Genotyping by PCR analysis was performed at post-
natal day 7 (p7) and additionally after euthanasia. Ear-
clip samples were digested using proteinase K (0.1
mg/mL in 30 mmol/L Tris-HCl pH 8.0 0.5% w/v SDS at
55°C for 16 hours; Sigma-Aldrich, Gillingham, UK), and
genomic DNA was purified by ethanol. A commercial
master mix containing Taq polymerase [1.1 ReddyMix
PCR master mix and 1.5 mmol/L MgCl2 (ABgene; Thermo
Scientific, Epsom, UK)] was used according to the man-
ufacturer’s instructions. Primers used for genotyping
mice were 5=-CGCACACACAGCTTCACCC-3= (mEPO
forward), 5=-CTGTAGGGCCAGATCACC-3= (mEPO re-
verse), and 5=-GCCTAGGCCTCCAAAAAAGC-3= (SV40T
reverse). Separate reactions were performed on each
ear-clip sample to determine the presence of the wild-
type mEPO allele and the SV40T allele.
The Mouse Model of Oxygen-Induced
Retinopathy
Nursing mothers and their pups were placed in a 75%
oxygen supply chamber from p7 to p12, as described
previously.13 A constant low flow of 80% oxygen (with the
balance as nitrogen) was provided to a closed acrylic
glass chamber. The oxygen level was monitored twice
daily, and maintained at 75%  3% O2. The mice were
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were collected at various time points after the return to
room air.
Measurement of Hematocrit
Hematocrit measurement was performed as a terminal
procedure, because of the limited blood volume in young
mice and the potential for induced anemia from repeated
blood sampling. Animals were terminally anesthetized,
and venous blood was obtained from the right atrium
immediately after death. Blood was collected directly into
heparinized microhematocrit capillary tubes (Hawksley;
Lancing, UK), to prevent clotting. Samples were spun at
5,400  g for 5 minutes in a microhematocrit centrifuge
(Biodynamics Selectafuge 24; BCL, Lewes, UK), and the
percentage packed cell volume (%PCV) was calculated
using a premeasured scale.
Supplementation with Recombinant
Human EPO
Supplementation with recombinant human erythropoietin
(rHuEPO) (Epoetin alfa, 40,000 U/mL; Janssen-Cilag,
High Wycombe, UK) was administered systemically by
intraperitoneal injection starting at p14 and ending at p25
at a dose rate of 5000 U/kg diluted in PBS, as described
previously.26,33 Each animal was weighed daily, and dos-
ing was administered per 0.1 g body weight in a maxi-
mum volume of 0.15 mL. Previous studies have shown
that systemic supplementation with erythropoietin in mu-
rine OIR from p14 to p16 does not affect the vascular
phenotype at p17.33
Electroretinography
Mice were anesthetized using an intraperitoneal injection
of a mixture containing medetomidine hydrochloride (1
mg/mL Domitor; Pfizer Animal Health, Kent, UK), ket-
amine (100 mg/mL; Fort Dodge Animal Health, Southam-
pton, UK), and sterile water in the ratio 5:3:42. Anesthesia
was reversed using an intraperitoneal injection of the
reversal agent atipamezole hydrochloride (Antisedan, 5
mg/mL; Pfizer Animal Health) in sterile water (ratio 1:50).
Electroretinography (ERG) was performed at p26 and
p60. Mice were dark-adapted for 16 hours. Animals were
anesthetized for ERG, and pupils were dilated using 1%
tropicamide (Minims; Bausch & Lomb, Kingston-on-
Thames, UK) applied topically. Water-based ocular lubri-
cant (Viscotears; Novartis Pharmaceuticals United King-
dom, Camberley, UK) was used to improve electrical
contact with the electrode and to keep the eyes moist
during the procedure. All manipulations before scotopic
ERG were performed under dim red-light illumination.
ERGs were obtained using an Espion ERG system (Di-
agnosys, Cambridge, UK). Ganzfeld ERGs were ob-
tained from both eyes simultaneously using contact plat-
inum corneal electrodes on each eye; one reference
electrode was placed sublingually, and the ground elec-
trode was placed subdermally in the midline at the baseof the tail. Electrical impedance was balanced for each
eye before recording (10 k). A scotopic flash intensity
series was performed, followed by light-adapted pho-
topic flicker measurements. In all measurements, 400 ms
of response was recorded. Recordings were filtered from
0 to 1 kHz and were digitized with a sampling frequency
of 5 kHz. The first 10 ms before the stimulus onset of each
recording was automatically used to set zero for the
trace.
For scotopic flash examination, a multiple white-light
flash intensity series was performed, with light intensity
increasing in six steps from 0.001 cd · s/m2 to 5 cd · s/m2.
Ten responses (for intensities 1 cd · s/m2) or five re-
sponses (for intensities 1 cd · s/m2) per intensity were
collected and averaged for use in subsequent analysis.
Measurements for amplitude and implicit time were taken
from the trough of the a-wave to the peak of the b-wave.
The photopic a-wave was defined as the maximal nega-
tive amplitude after the onset of light exposure. The pho-
topic b-wave was defined as the maximal positive ampli-
tude after the onset of light exposure, compensating
visually for the waveforms of the OPs. Statistical compar-
ison was performed at the 1 cd · s/m2 intensity represent-
ing a mixed rod-cone response46 and provided the max-
imal a-wave amplitude. OPs were obtained with a fifth-
order Butterworth filter and 65- to 235-Hz bandpass using
a custom-made program coded in MATLAB (MathWorks,
Natick, MA), as described previously.8,46 OP 1 was not
analyzed, because of the potential for a-wave contami-
nation. Analysis of OPs was performed to determine the
sum of the OP amplitudes of OP 2 to 5 (SOPA).8 The OPs
were also analyzed in the frequency domain by using a
fast Fourier transformation with the first 128 ms of each
recording, previously filtered with a fifth-order Butterworth
filter as detailed previously. This produced a power spec-
trum distribution that was calibrated as described previ-
ously.8 The resulting calibrated data were fit by a Gauss-
ian curve; the area under the curve was calculated and
used to quantify OP energy, as described previously.8
Photopic flicker examination was performed on light-
adapted (10 minutes light adaptation time, 10 cd/m2 in-
tensity) mice after scotopic recording. A photopic flicker
frequency series (from 0.5 to 15 Hz) was performed with
a standard bright white light (3 cd · s/m2 with a back-
ground intensity of 10 cd/m2). Analysis was performed on
the average recording made from 25 recordings per fre-
quency. Analysis of cone flicker amplitude and implicit
time was performed on photopic flicker ERGs at the
10-Hz frequency, because according to previous report
this is the maximal amplitude in the mouse flicker ERG.47
Amplitudes were measured from the trough of the a-wave
to the peak of the b-wave, and an average of three
measurements was used in subsequent analysis.
Histology and Immunohistochemistry
For lectin staining of retinal vasculature in retinal flat-
mounts, eyes were fixed in 4% paraformaldehyde for 1
hour, and the lens and cornea were removed. Eyecups
were washed and then incubated with 0.1 mg/mL tetra-
methylrhodamine isothiocyanate-conjugated Bandeiraea
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4°C. Retinas were dissected from the eyecup, radial cuts
were made to flatten the retina, and the retinas were
mounted with fluorescent aqueous mounting medium
(Dako, Ely, UK), ganglion cell layer uppermost, using a
coverslip. Lectin-stained retinal flatmounts from p12 and
p17 mice from the OIR model were assessed as de-
scribed previously.48,49 Retinas were imaged using a
Zeiss LSM 510 confocal microscope at 5 magnification
(Carl Zeiss Microimaging, Göttingen, Germany). A single
x/y plane was taken from each quadrant of the retina and
the central retina at 1024  1024 pixel resolution. Com-
posite images were constructed using Photoshop CS2
software (Adobe Systems, Uxbridge, UK). Images were
loaded into an image analysis program (Image Pro Plus;
Media Cybernetics, Bethesda, MD) and converted to 16-
bit grayscale images. The total vascularized retina and
the capillary-free area were delineated and the areas
were calculated. Areas of neovascularization were out-
lined, and the manual selection tool was used to highlight
the bright neovascular areas only. The neovascular and
ischemic areas were represented as percentages of total
retinal area; these values were used in subsequent analysis.
The TUNEL procedure for detection of DNA fragmen-
tation (a marker of apoptosis) was performed using a
commercial kit according to the manufacturer’s instruc-
tions (Chemicon ApopTag Red in situ apoptosis detection
kit; Millipore, Livingston, UK). For quantification of apop-
totic nuclei, the number of apoptotic cells was counted in
each retinal layer in three 12-m central retinal cryosec-
tions, 60 m apart. An average value per eye (and per
animal, if both eyes were examined) was calculated and
used in subsequent analysis.
For pimonidazole immunohistochemistry, 60 mg/kg pi-
monidazole hydrochloride (Chemicon Hypoxyprobe-1;
Millipore) diluted in sterile PBS was administered by in-
traperitoneal injection 3 hours before euthanasia, as de-
scribed previously.48,50 Animals were euthanized and
eyes were fixed by perfusion with 4% paraformalde-
hyde. Retinal cryosections were incubated with fluo-
rescein isothiocyanate-conjugated anti-pimonidazole
antibody [Chemicon (Millipore)] at a dilution of 1:50 for
1 hour at room temperature.
Collagen IV immunostaining of retinal vasculature was
performed on retinal cryosections. Anti-collagen IV anti-
body (AbD Serotec, Oxford, UK) was incubated at a
dilution of 1:300 for 16 hours at 4°C, followed by anti-
rabbit secondary antibody (goat anti-rabbit Alexa Fluor
594; Invitrogen Molecular Probes, Paisley, UK) incubated
at room temperature for 1 hour at a dilution of 1:200.
For analysis of retinal thickness, enucleated eyes were
fixed in Serra’s fixative [60% (v/v) ethanol, 30% (v/v)
saturated formaldehyde, 10% (v/v) concentrated acetic
acid] at 4°C for 16 hours and then were embedded in
paraffin using an automated tissue-processing system
(TP1020; Leica Microsystems, Wetzlar, Germany). Sec-
tions 6 m thick were stained with H&E, and three central
sagittal retinal sections per eye were selected that tran-
sected the optic nerve. Sections were photographed using
a light microscope (Leitz Diaplan microscope; Leica Micro-
systems) equipped with a QImaging MicroPublisher 5.0digital camera and QCapture Pro software version 6.0
(QImaging, Surrey, BC, Canada) at 40 magnification. A
calibration slide with 10-m gradations was imaged at
the same resolution, to facilitate measurement. Measure-
ments were taken at 150-m intervals either side of the
optic nerve head toward the periphery. Measurement
was performed using commercial image analysis soft-
ware (Image-Pro Plus version 5.1; Media Cybernetics,
Bethesda, MD). For each region, the total retinal thick-
ness from the edge of the nerve fiber layer to the outer
edge of the outer nuclear layer was measured. Individual
measurements were made for the nerve fiber layer, inner
plexiform layer, inner nuclear layer, outer plexiform layer,
and outer nuclear layer.
Real-Time RT-PCR
RNA was extracted from mouse retinal tissue (n  3 eyes
per group) using a commercial kit (RNeasy mini kit; Qia-
gen, Crawley, UK). The amount of template RNA was
measured using a small-volume spectrophotometer
(NanoDrop ND-1000; Thermo Scientific, Wilmington, DE).
Equal amounts of RNA were used for all samples as a
template for cDNA manufacture. cDNA was made from
template RNA using a commercial kit (QuantiTect Re-
verse Transcriptase Kit; Qiagen). Real-time quantitative
RT-PCR was performed using an ABI 7900HT thermal
cycler with its associated software, SDS version 2.2.2
(Applied Biosystems, Foster City, CA). The 5= nuclease
technique based on Taq polymerase and FAM labeled
hydrolysis probes was used for all real-time reactions,
using commercially designed primer/probe combinations
(Roche Universal Probe Library; Roche Diagnostics, Bur-
gess Hill, UK). The mEPO primers were 5=-TCTGCGA-
CAGTCGAGTTCTG-3= (forward) and 5=-CTTCTGCA-
CAACCCATCGT-3= (reverse); the probe sequence used
was 5=-GGAGGCAG-3= (probe #16; Roche Diagnostics).
The EPO real-time assay was designed to detect both
wild-type EPO and Epo-Tag RNA. All reactions were per-
formed in triplicate. For all test samples, the endogenous
control -actin was used to verify equal loading and to
facilitate relative quantitation calculation. The m-actin
primers were 5=-AAGGCCAACCGTGAAAAGAT-3= (for-
ward) and 5=-GTGGTACGACCAGAGGCATAC-3= (re-
verse); the probe sequence was 5=-TGCTGTCC-3= (probe
#56; Roche Diagnostics). The 		CT method of relative
quantitation was used to compare data.
ELISA
After terminal anesthesia, mice were perfused with 20 mL
of PBS to remove residual blood from the vasculature.
Whole eyes were snap-frozen in liquid nitrogen. Eyes
were homogenized in sterile PBS with protease inhibitors
(Sigma-Aldrich) using a plastic homogenizer. The ho-
mogenate was spun at 2800  g for 10 minutes. Protein
concentration of the supernatant was determined using a
colorimetric protein assay performed in triplicate (DC
protein assay kit; Bio-Rad Laboratories, Hemel Hemp-
stead, UK) and compared with a bovine serum albumin
standard curve. Sample endpoint enzyme-linked immu-
1730 Mowat et al
AJP April 2012, Vol. 180, No. 4nosorbent assay (ELISA) was measured in triplicate us-
ing an EMax microplate reader (Molecular Devices, Berk-
shire, UK), comparing the optical density at 450 nm with
a reference at 650 nm. The quantity of murine erythropoi-
etin (mouse erythropoietin Quantikine ELISA development
kit; R&D Systems, Minneapolis, MN) or human erythropoie-
tin (human erythropoietin Quantikine ELISA development
kit; R&D Systems) was calculated per milligram of whole-
eye protein, comparing each sample to a bovine serum
albumin (10 mg/mL; New England Biotechnology, Hitchin,
UK) standard curve of known concentration.
Statistical Analysis
For data obtained from both eyes, the mean value per
animal was calculated and used in subsequent analysis.
Unpaired Student’s t-tests were used when two un-
matched groups were compared. One-way analysis of
variance was used to compare three unmatched groups.
Two-way analysis of variance was used when compari-
sons were made with two or more interconnected vari-
ables (eg, oxygen treatment and genotype). The Bonfer-
roni post hoc test was used to examine differences
further. For data presented in figures, the statistical test
used is specified along with the P values. A P value of
0.05 was considered significant. Statistical analysis
was performed using a commercial program (GraphPad
Prism version 5.00 for Windows, San Diego, CA). Data in
graphs are expressed as means  SEM.
Results
EPO Expression Is Up-Regulated in the Eye and
the Kidney during OIR
In OIR, exposure of mouse pups to a hyperoxic environ-
ment (75% oxygen) from p7 to p12 results in capillary
ablation in areas of the central retina. On return to room
air at p12, these areas of retinal ischemia become hy-
poxic, and the associated up-regulation of proangiogenic
cytokines leads to aberrant, preretinal neovasculariza-
tion.13,50 To investigate the effect of hypoxia in OIR on
expression of EPO, we used real-time RT-PCR to mea-
sure EPO mRNA in the eyes of Epo-Tag/ and Epo-
Tag/ littermates with OIR at p13 and in control animals
raised in normoxia throughout. To identify any effect on
systemic expression of EPO, we also measured renal
EPO mRNA. The return to room air from hyperoxia was
associated with up-regulated expression of EPO at p13 in
both eyes and kidneys of both Epo-Tag/ and Epo-
Tag/ animals (Figure 1A). This finding suggests that
hypoxia in this model is not limited to the retina and has
potentially relevant systemic effects. The up-regulated
expression of EPO in OIR was significantly less marked in
the eyes and kidneys of Epo-Tag/ animals than in
those of Epo-Tag/ littermates (Figure 1A), confirming
that these mice have a blunted EPO response to hypoxia.
To evaluate the effect of EPO up-regulation on ocular
EPO protein concentration, we also examined whole eyes
for EPO protein by ELISA (n  8 independent eyes pergroup). The concentration of EPO in eyes of Epo-Tag/
mice at p13 was significantly higher in OIR than in control
animals raised in normoxia throughout (Figure 1B). The
concentration of EPO in eyes of Epo-Tag/ mice after
OIR at p13 was significantly lower than in Epo-Tag/ litter-
mates. These findings confirm that the lack of significant
EPO up-regulation in response to hypoxia in Epo-Tag/
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Figure 1. OIR is associated with up-regulation of EPO mRNA and protein in
the kidney and the retina. A: At p13, both renal and retinal EPO mRNA were
up-regulated after OIR in both Epo-Tag/ and Epo-Tag/ mice, but Epo-
Tag/ mice had significantly greater up-regulation in OIR than Epo-Tag/
mice (n 3 per group). B: Epo-Tag/mice also had a blunted EPO protein
presence after OIR in contrast to Epo-Tag/ mice as shown by whole-eye
EPO protein ELISA at p13 (n  8 per group). C: A mild but significant
reduction in hematocrit (%PCV) was observed in both Epo-Tag/ and
Epo-Tag/ mice after OIR at p13 (n  4 per group). *P  0.05, **P  0.01,
and ***P  0.001 two-way analysis of variance with Bonferroni correction for
multiple analyses. K, kidney; R, retina.mice is associated with a deficiency of intraocular EPO.
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might be compromised in Epo-Tag/ mice, we mea-
sured the hematocrit (%PCV) in animals at p13. The he-
matocrit was lower in mice with OIR (33.5  0.3% for
Epo-Tag/ versus 32  0.6% for Epo-Tag/; n  4 per
group) than in normoxic controls (38.2  0.6% for Epo-
Tag/ versus 36.3  1.3% for Epo-Tag/; n  4 per
group), but we detected no significant difference in he-
matocrit between Epo-Tag/ and Epo-Tag/ litter-
mates (Figure 1C).
Body weight at p13 did not differ between Epo-Tag/
and Epo-Tag/ in normoxia or after OIR (data not
shown). Wild-type animals were significantly smaller at
p13 in OIR, compared with normoxic controls (5.7 
0.05 g OIR versus 7.3  0.3 g normoxic, P  0.05).
EPO Deficiency in Epo-Tag/ Mice Does
Not Attenuate Ischemia-Induced Retinal
Neovascularization in OIR
To investigate the effect of EPO deficiency on ischemia-
induced retinal neovascularization, we examined B. sim-
plicifolia lectin-stained retinal flatmounts of Epo-Tag/
mice with OIR. To identify the effect of hyperoxia on
capillary ablation, we measured the ischemic area in
retinal flatmounts at p12 after OIR (n  8 independent
eyes per group); representative flatmounts are shown in
Figure 2, A and B. To investigate the effect on neovas-
cularization, we measured the ischemic and neovascular
areas at p17; representative flatmounts are shown in Fig-
ure 2, C and D. Epo-Tag/mice developed a marginally
greater (3.5% greater) area of retinal capillary ablation at
p12, compared with Epo-Tag/ littermates (Figure 2E).
At p17, however, there were no significant differences
between genotype in retinal ischemic area or neovascular
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These data suggest that relative EPO deficiency in Epo-
Tag/ mice during the hyperoxic phase of OIR may
contribute marginally to additional capillary ablation, as
has been previously demonstrated,33 but that this relative
deficiency of endogenous EPO in the hypoxic phase of
OIR does not prevent the typical aberrant retinal neovas-
cular response to hypoxia in this model.
OIR Is Associated with Substantial Inner Retinal
Apoptosis in Areas of Ischemia/Hypoxia and
Mild Apoptosis throughout the Outer Retina
To define the influence of ischemia/hypoxia on neuroreti-
nal degeneration in OIR, we investigated apoptosis by
TUNEL staining of retinal cryosections at time points dur-
ing OIR development. At p13, apoptosis in both the inner
and outer nuclear layers was increased in animals with
OIR, compared with those raised in normoxia throughout
(Figure 3).
The density of inner nuclear layer apoptotic cells cor-
related closely with the area of capillary ablation and
hypoxia, as demonstrated by the absence of collagen
IV-stained vasculature and the strength of pimonidazole
binding (Figure 3, A and B). Greater numbers of TUNEL-
stained cells were evident in the inner nuclear layer of
both Epo-Tag/ and Epo-Tag/ animals at p13 in OIR,
compared with control animals raised in normoxia
throughout (n  8 per group; Figure 3C).
Apoptotic cells in the outer nuclear layer at p13 were
distributed across the retina and were not restricted to
areas of inner retinal ischemia/hypoxia. Greater numbers
of TUNEL-stained cells were evident in the outer nuclear
layer of both Epo-Tag/ and Epo-Tag/ animals at p13
in OIR, compared with control animals raised in normoxia
 OIR
OIR
+/-
Figure 2. OIR-induced ischemia and neovascu-
larization is minimally affected in Epo-Tag/
animals. The mice were subjected to OIR from
p7 to p12. A to D: Representative retinal flat-
mounts are shown for p12 and p17. A: Epo-
Tag/ (n  8). B: Epo-Tag/ (n  8). C:
Epo-Tag/ (n  10). D: Epo-Tag/ n  11).
Upper images show staining for vasculature (te-
tramethylrhodamine isothiocyanate-conjugated
B. simplicifolia lectin); lower images show the
corresponding areas of ischemia (central filled
area) and neovascularization (diffuse white ar-
eas highlighted within vascularized retinal area).
Scale bar  500 m. E to G: Quantification of
ischemia at p12 was slightly higher in Epo-
Tag/ mice (E), but by p17 neither ischemia
(F) nor neovascularization (G) were significantly
different compared with wild-type littermates.
*P  0.05 unpaired t-test.+/+
+/- 
17
D
+/-
p17throughout (n  8 per group; Figure 3D). The increase in
1732 Mowat et al
AJP April 2012, Vol. 180, No. 4apoptosis at this time point represented a very small
proportion of the outer nuclear layer cells, and no differ-
ence was detected at the p17 time point.
We detected no difference in the number of apoptotic
cells between Epo-Tag/ and Epo-Tag/ littermates at
p12  6 hours, at p13, or at p17 (n  3 per group; Figure
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Figure 3. Hypoxia in OIR is associated with retinal apoptosis. Retinas from
Epo-Tag/ mice raised in normoxia (A) and OIR 24 hours (B) after return
to room air at p13 were evaluated to determine the extent and distribution of
apoptosis. Immunohistochemistry was performed for apoptotic nuclei
(TUNEL; red), hypoxic protein (pimonidazole; green), and retinal vasculature
(collagen IV; white). Staining was performed on 12-m frozen retinal sec-
tions. Boxed regions at the left are shown at higher magnification at the
right (c, central; p, peripheral). Arrows indicate apoptotic cells; an arrow-
head in the bottom panels indicates the position of the inner limiting
membrane. C andD: Apoptosis at p12 6 hours, p13 and p17 was quantified
in all retinal layers in both Epo-Tag/ and Epo-Tag/ mice (n  8 per
group). OIR at p13 was associated with a significant increase in apoptosis in
the inner retina (C) and outer retina (D) in both Epo-Tag/ and Epo-Tag/
mice. gcl, ganglion cell layer; inl, inner nuclear layer; onh, optic nerve head;
onl, outer nuclear layer; os, ora serrata. *P  0.05, ***P  0.001 two-way
analysis of variance with Bonferroni post hoc test. Scale bars: 250 m (A and
B, left); 50 m (A and B, right).3, C and D). Apoptosis in the retinal pigment epitheliumand ganglion cell layer was unaffected by OIR in Epo-
Tag/ and Epo-Tag/ animals, and we identified no
difference in the number of apoptotic cells between Epo-
Tag/ and Epo-Tag/ wild-type mice (data not shown).
Inner Retinal Ischemia/Hypoxia Results In Focal
Retinal Degeneration and Sustained Activation
of Retinal Müller Glia
To evaluate the long-term consequences of local retinal
ischemia/hypoxia on retinal morphology, we examined
retinas from animals at p60. To determine the effect of
ischemia/hypoxia in OIR on the thickness of the retinal
layers, we examined paraffin-embedded retinal sections
from Epo-Tag/ mice and Epo-Tag/ littermates that
had been raised in normoxia or undergone OIR (n  5 or
6 animals per group). OIR induced considerable thinning
of the central retina, in a configuration that correlates
closely with the area of ischemia/hypoxia in this model.
Total retinal thickness was substantially less in animals
with OIR than in normoxic controls (Figure 4A). Significant
thinning was detected in the nerve fiber layer (Figure 4B),
inner plexiform layer (Figure 4C), inner nuclear layer (Fig-
ure 4D), and outer plexiform layer (Figure 4E). We mea-
sured no effect of OIR on thickness of the outer nuclear
layer (Figure 4F). We detected no differences in thick-
ness of retinal layers between Epo-Tag/ and wild-type
littermates in any region of the retina in OIR or in control
animals raised in normoxia. Representative images are
shown from retinas of a normoxic Epo-Tag/ animal in
Figure 4G and from an Epo-Tag/ mouse with OIR in
Figure 4H.
To investigate the effect of OIR on activation of retinal
glia, we performed immunohistochemistry for glial fibrillar
acidic protein in animals at p60 (GFAP) (n  4 animals
per group). All glial cells were labeled using vimentin. In
retinas of wild-type animals raised in normoxia, GFAP
labeled only astrocytes, with very few glial cells labeled
throughout the retina, except at the retinal periphery (Fig-
ure 4, I and J). In contrast, in retinas of animals with OIR,
we found the majority of glial cells to be activated, with
GFAP-positive cells throughout the retina (Figure 4, K and
L). Up-regulation of GFAP in glia was detected at p17 in
the central retina, and at p26 extending beyond pre-
sumed areas of hypoxia (see Supplemental Figure S1 at
http://ajp.amjpathol.org). We detected no differences in
glial activation between Epo-Tag/ and Epo-Tag/
wild-type animals.
OIR Results in Sustained Dysfunction of the
Inner Neuroretina, and EPO-Deficient
Epo-Tag/ Mice Also Develop Dysfunction
of the Outer Neuroretina
To determine the effect of OIR on neuroretinal function,
we performed scotopic (dark-adapted, rod-mediated)
and photopic (light-adapted, cone-mediated) ERGs in
Epo-Tag/ mice and Epo-Tag/ littermates (n  4 to 9
animals per group). Representative ERG waveforms are
nal magn
uclear l
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AJP April 2012, Vol. 180, No. 4shown from Epo-Tag/mice at p26 (Figure 5A) and p60
(Figure 5B). After OIR, Scotopic ERG a-wave and b-wave
amplitudes at p26 and p60 were significantly reduced in
Epo-Tag/ and Epo-Tag/ animals, compared with
Epo-Tag/ or Epo-Tag/ animals raised in normoxia
(Figure 5, C and D). There was no difference in body
weight between any groups at p26 (data not shown).
Epo-Tag/ mice with OIR had significantly lower a-
wave and b-wave amplitudes at both p26 and p60,
compared with Epo-Tag/ littermates with OIR, indi-
cating inhibition of both inner and outer retinal function
(Figure 5, C and D). The reduction in b/a wave ratio
after OIR at p26 and p60 was proportional in both
genotypes (Figure 5E), which is consistent with a pref-
erential and sustained dysfunction of the inner retina, a
characteristic of severe ischemic retinopathies in hu-
G normoxia H OIROS
ONH ONH
OS GF
vim
Ho
I  normoxia
A  total retinal thickness B  nerve fiber la
D inner nuclear layer E outer plexifor
0
20
40
60
80
100
120
140
160
peri 1.95 1.65 1.35 1.05 0.75 0.45 0.15 0 0.15 0.45 0.75 1.05 1.35 1.65 1.95 peri
0
2
4
6
8
10
12
14
16
18
0
5
10
15
20
25
30
35
40
0
2
4
6
8
10
12
14
16
18
+/+ normoxia
+/- normoxia
+/- OIR
+/+ OIR
distance from optic nerve head (mm)
th
ic
kn
es
s 
(μ
m
)
distance
distance from optic nerve head (mm) distance
peri 1.95 1.65 1.35 1.05 0.75 0.45 0.15 0 0.15 0.45 0.75 1.05 1.35 1.65 1.95 peri peri 1.95 1.65 1.35 1.05 0.75 0
peri 1.95 1.65 1.35 1.05 0.75 0
th
ic
kn
es
s 
(μ
m
)
th
ic
kn
es
s 
(μ
m
)
th
ic
kn
es
s 
(μ
m
)
* *** * *
*
*
*
* *
*
**
*
*
*
*
**
**
***
*
* *
** **
**
**
***
***
Figure 4. OIR is associated with retinal thinning and sustained glial stress. M
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(Epo-Tag/); inl, inner nuclear layer; ONH, optic nerve head; onl, outer nmans.51 In comparison with Epo-Tag/ mice, Epo-Tag/ mice had additional reductions in a-wave am-
plitude (Figure 5C), with corresponding b-wave
amplitude reductions (Figure 5D). This finding indi-
cates that EPO deficiency might contribute to addi-
tional outer neuroretina dysfunction after OIR.
Analysis of OPs from scotopic ERGs demonstrated
that the sum of the peak OP amplitude of OPs 2 to 5
(Figure 5F) and OP energy (Figure 5G) at p26 and p60
were significantly reduced by OIR in both Epo-Tag/
and Epo-Tag/ littermates. Because OP waveforms (ex-
cluding OP 1, which was not analyzed in the present
study) are predominantly derived from inner retinal syn-
aptic activity,47 the reduced amplitudes demonstrate
specific impairment of inner retinal function in OIR. How-
ever, no differences in OP characteristics were detected
between Epo-Tag/ and Epo-Tag/ littermates (Figure
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Figure 5. OIR is related to sustained inhibition of scotopic and photopic retinal function, EPO deficiency exacerbates retinal dysfunction. A and B: Representative
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AJP April 2012, Vol. 180, No. 4effect of EPO deficiency in OIR could be a consequence
of outer retinal dysfunction.
Evaluation of photopic flicker ERGs showed that am-
plitudes were significantly reduced in animals with OIR at
both p26 and p60 (Figure 5H), suggesting a significant
effect of hypoxia on cone photoreceptor function. At p26,
Epo-Tag/ animals had significantly lower photopic
flicker amplitudes than Epo-Tag/ littermates, although
by p60 this difference was not statistically significant.
Systemic EPO Replacement Rescues Retinal
Dysfunction Associated with EPO Deficiency
To determine whether retinal dysfunction at p26 in Epo-
Tag/ mice is a consequence of EPO deficiency, we
investigated whether retinal function is protected by sys-
temic delivery of recombinant EPO. We measured the
effect of OIR on Epo-Tag/ mice treated with rHuEPO
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First, we determined the effect of EPO supplementa-
tion on hematocrit by measuring the %PCV at p26 (during
dosing) and at p60 (35 days after the most recent dose)
(n  3 per group). At p26, administration of rHuEPO
resulted in a significant increase in hematocrit (Figure
6B). At p60, the effect of rHuEPO on hematocrit was no
longer apparent (n  6 per group; Figure 6B).
To determine the amount of rHuEPO reaching the eye
after intraperitoneal delivery, we measured the ocular con-
centration of rHuEPO by ELISA of eyes from animals at p26
(n  3 per group; Figure 6C), 4 hours after intraperitoneal
injection of either PBS or rHuEPO. We detected small
amounts of rHuEPO in eyes from animals injected with
rHuEPO (0.027  0.007 mIU/mL rHuEPO per milligram of
protein). No rHuEPO was detected in eyes from animals
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AJP April 2012, Vol. 180, No. 44.272 mIU/mL rHuEPO per milligram of protein) than in the
eye, and were significantly higher compared with PBS-
treated animals (0.52  0.2 mIU/mL rHuEPO per milligram
of protein) (Figure 6C). These data indicate that system-
ically delivered (intraperitoneal) rHuEPO achieves lower
concentrations in the eye than in the spleen.
To investigate the effect of rHuEPO supplementation
on local production of EPO in the tissue, we performed
real-time RT-PCR for mEPO on retinas and kidneys from
Epo-Tag/ animals and PBS or rHuEPO treated Epo-
Tag/ animals at p26 (24 hours after injection). Intraper-
itoneal injection of rHuEPO in Epo-Tag/ mice resulted
in significant suppression of renal EPO expression, but
no measureable suppression of retinal EPO expression
(Figure 6D). These data suggest that systemically deliv-
ered EPO has a negative feedback effect on local pro-
duction of EPO in the kidney, but not in the eye.
To determine the effect of systemic rHuEPO adminis-
tration on retinal function, we performed ERGs at p26 and
p60 (n  10, Epo-Tag/ untreated; n  7, Epo-Tag/
PBS-treated; n  8, Epo-Tag/ rHuEPO treated). Intra-
peritoneal administration of rHuEPO rescued the reduced
a-wave amplitude in Epo-Tag/ mice with OIR at p26 to
a level similar to that of wild-type animals with OIR (Figure
6E) and also led to a proportional rescue of the b-wave
amplitudes (Figure 6F); however, these effects were not
sustained beyond the period of rHuEPO administration at
p60 (Figure 6, E and F). Photopic flicker amplitudes were
unaffected by rHuEPO treatment in Epo-Tag/, com-
pared with PBS-treated littermates at p26 or p60 (Figure
6G). Body weight did not differ significantly between
groups at p26 (data not shown). Overall, these data sug-
gest that the transient rescue effect of systemic EPO in
Epo-Tag/ mice correlates well with the changes ob-
served in the systemic hematocrit levels. These data also
indicate that the retinal dysfunction in Epo-Tag/ mice
can be attributed directly to EPO deficiency, and not to a
toxic effect of the SV40T insertion.
To investigate whether systemic supplementation with
EPO in non-EPO-deficient animals can rescue the neu-
roretinal dysfunction induced by OIR, we administered
rHuEPO systemically to Epo-Tag/ animals with OIR
from p14 to p25, but found no evidence of any rescue of
the ERG abnormalities (see Supplemental Figure S2 at
http://ajp.amjpathol.org).
Discussion
With the present study, we have identified and quantita-
tively measured the neuroretinal consequences of OIR in
terms of both retinal dysfunction and degeneration. We
have demonstrated that OIR in the mouse induces both
neuroretinal degeneration and sustained retinal dysfunc-
tion that affects predominantly the inner retina. OIR is
associated with up-regulated expression of endogenous
EPO in both the retina and kidney at p13, and with a
reduction in hematocrit. We investigated the role of EPO
in ischemia-induced retinopathy using EPO-deficient
Epo-Tag/ transgenic mice. We found that EPO defi-
ciency in these animals did not affect the vascular re-sponse to OIR or exacerbate the inner retinal degenera-
tion, but resulted in exaggerated neuroretinal dysfunction
affecting predominantly the outer retina (as demon-
strated by reduced scotopic a- and b-wave amplitudes
and photopic flicker amplitudes). This dysfunction could
be rescued by systemic administration of rHuEPO. We
conclude that endogenous EPO protects against retinal
dysfunction in OIR by increasing oxygen delivery to the
eye, but found no evidence that systemic supplementa-
tion in EPO-competent mice provides additional benefi-
cial effects.
Retinal ischemia in OIR is associated with the induction
of apoptosis (which is most pronounced in cells of the
inner nuclear layer) and is associated with retinal isch-
emia/hypoxia both spatially and temporally. Although ex-
posure to hyperoxia can induce retinal apoptosis direc-
tly,52–55 the absence of significant apoptosis in any retinal
layer immediately after the 5 days of hyperoxia (at p12 
0 hours) and the onset of apoptosis shortly after with-
drawal from hyperoxia suggest that the cell death is the
result of ischemia/hypoxia and not hyperoxia. In other
models of vascular occlusion, retinal ischemia results in
high levels of inner retinal apoptosis within 24 hours.10,56
We have found that the peak of apoptosis in OIR occurs
before p17, although retinal ischemia is evident also after
this stage.13
Apoptosis of cells in the inner retina during ischemia/
hypoxia in OIR is associated with thinning of the inner
nuclear layer, nerve fiber layer, and inner and outer plex-
iform layers in the central retina. This is consistent with
reports that insufficiency of the superficial and deep ret-
inal vascular plexus results in degeneration of the inner
and outer plexiform layers, respectively.57,58 The distri-
bution of degeneration of the inner retina in OIR is re-
stricted to the central retina, consistent with a direct effect
of ischemia/hypoxia in this area. The supply of oxygen to
the plexiform layers in the developing eye is limited by
incomplete vascular development, and even in adult an-
imals the oxygen tension in these layers of the retina is
relatively low.59,60 OIR results in delayed development of
the deep vascular plexus,61 which could contribute to
hypoxia-induced degeneration of the outer plexiform
layer.
Previous studies have demonstrated that EPO can pro-
tect the retina against ischemic injury38 and against light-
induced retinal degeneration.26,39 Others have described
dose-dependent antiapoptotic and neuroprotective ef-
fects of intraocular EPO administration.41,62 In the pres-
ent study, ischemia-induced degeneration of the inner
retina was not exacerbated by endogenous EPO defi-
ciency in Epo-Tag/ mice with OIR. This finding does
not, however, exclude a neuroprotective effect of EPO in
OIR, because the EPO deficiency in these animals is
incomplete. Although Epo-Tag/ mice are deficient in
EPO, they are nonetheless able to maintain low-level EPO
expression and demonstrate up-regulated EPO expres-
sion in response to hypoxia.
In animals with OIR, we detected an increased fre-
quency of apoptosis in cells in the outer nuclear layer
(which comprises nuclei of photoreceptor cells) within 24
hours of the onset of retinal hypoxia/ischemia. Only a
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AJP April 2012, Vol. 180, No. 4small proportion of the cells were apoptotic, and we did
not detect any associated effect on outer nuclear layer
thickness at p60. The outer nuclear layer depends for its
function and survival on normal perfusion of the choroidal
circulation.60 The mechanism of photoreceptor apoptosis
during retinal ischemia in OIR is not clear, but may be a
consequence of choroidal degeneration63 or of slightly
reduced hematocrit leading to photoreceptor hypoxia,
apoptosis, and corresponding functional deficits.63
We identified sustained neuroretinal dysfunction in mu-
rine OIR, as demonstrated by reduced scotopic and pho-
topic ERG responses. Substantial reductions in ERG b-
wave amplitudes, b/a wave ratio, and OPs indicating
inner retinal disease are consistent with dysfunction and
degeneration associated with retinal ischemia. The re-
duced amplitude of OPs in murine OIR is consistent with
changes previously reported in rat OIR.8 In addition, we
detected a reduction in ERG a-wave, indicating dysfunc-
tion of photoreceptor cells. An effect on light-adapted
ERG responses indicates a negative effect on the func-
tion of cone photoreceptors. OIR is generally considered
to be a disorder of the retinal vasculature, and an effect
on photoreceptor function in mice has not previously
been described. Future studies could use the techniques
presented here to investigate neuroprotective agents or
to evaluate potential neuronal adverse effects of antian-
giogenic treatments.
We detected no retinal dysfunction in Epo-Tag/
mice reared in normoxia, suggesting that normal EPO
expression is not critical for retinal function in normal
conditions. However, EPO deficiency in Epo-Tag/mice
was associated with a significantly more pronounced ef-
fect on ERG a-wave and b-wave amplitudes in OIR. The
lack of a significant difference in b/a wave ratio or addi-
tional OP abnormalities suggests that the particular vul-
nerability of EPO deficiency in OIR can be attributed
predominantly to dysfunction of the outer retina. Cone
photoreceptor responses were significantly reduced in
Epo-Tag/mice at p26, but showed significant recovery
by p60, indicating that the insult that leads to a reduction
in cone function is temporary, allowing the cones to re-
cover by day 60.
The EPO deficiency in Epo-Tag/ mice was not as-
sociated with a significant effect on the typical retinal
vascular response to OIR. These animals developed a
slightly larger area of retinal ischemia after exposure to
oxygen, but demonstrated a typical neovascular re-
sponse to hypoxia by p17. There is considerable variabil-
ity in the proangiogenic activity of EPO, which is contex-
tual and depends on the species,62,64 the stage of
OIR,17,18,33 and the EPO subtype.65 Differences in the
effects of EPO supplementation on retinal vasculature
between these reports and the present findings may re-
flect differences in the nature of the EPO preparation, in
the dose, timing, and route of delivery, and in the models
used. In the present study, EPO deficiency in Epo-Tag/
mice in OIR was incomplete, and residual EPO activity
may be sufficient to induce appropriate angiogenesis in
this context or to facilitate the activity of other potent
angiogenic factors inducing neovascularization (such as
VEGF).66 The effects of EPO are also dependent on thesite of EPO receptor (EPO-R) expression. Previous stud-
ies have identified EPO-R expression in retinal ganglion
cells,67 Müller glia,68 and retinal photoreceptors.26,39 The
nature of the retinal disease process may affect the lo-
cation and extent of EPO-R expression.28,69 The distribu-
tion of EPO-R expression in mouse OIR, however, has yet
to be described.
The protection of Epo-Tag/ mice against retinal dys-
function in OIR by systemic rHuEPO supplementation
was associated with an increase in hematocrit. rHuEPO
administered systemically could be detected at very low
concentrations in the eye, compared with the spleen, and
significantly suppressed renal but not retinal expression
of endogenous EPO. These data indicate that the addi-
tional outer retinal dysfunction apparent in EPO-deficient
Epo-Tag/ mice with OIR may be a result of impaired
oxygen delivery to the outer retina. Outer retinal dysfunc-
tion occurs secondary to systemic hypoxia, with sparing
of the inner retina through compensatory autoregulation
of blood flow within the inner retinal circulation.70 Sys-
temic but not intraocular EPO supplementation protects
retinal photoreceptor cells against light-induced damage
and against certain hereditary retinal degenerations.71
Another role for EPO in neuroprotection might be its in-
hibitory effect on microglial activation. EPO deficiency
would be expected to contribute further to the enhanced
microglial activation seen in mouse OIR.72 These effects
could directly affect microglial phagocytic activity, or in-
directly affect release of proinflammatory cytokines, al-
though recent studies in the brain suggest that cytokine
effects of EPO are less significant than those on micro-
glial proliferation.73 Microglial activation can protect
against photoreceptor degeneration,74 and it is conceiv-
able that the effect of EPO deficiency on increased retinal
microglial activity may have contributed to the enhanced
photoreceptor dysfunction that we observed.
In the present study, EPO deficiency in Epo-Tag/
mice was compatible with normal retinal function in nor-
moxia as measured by electroretinography, but it exac-
erbated ischemic injury in OIR. Dysfunction of the outer
retina may reflect impaired oxygen delivery secondary to
anemia in Epo-Tag EPO-deficient mice with OIR, given the
uniquely high demand of photoreceptor cells for oxygen.
The present findings raise the possibility that systemic
rHuEPO supplementation therapy for anemia of prematurity
might protect outer retinal function against ischemic injury in
retinopathy of prematurity without exacerbating the devel-
opment of pathological neovascularization.75
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